Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-09-21
2009-06-16
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S231500, C514S315000, C514S316000, C514S317000, C514S318000, C514S336000, C544S096000, C544S124000, C546S208000, C546S209000, C546S186000, C540S450000, C540S484000, C540S544000, C540S596000
Reexamination Certificate
active
07547693
ABSTRACT:
Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1and X2independently represent a nitrogen atom or CH; Y represents a specific group; X3represents Os—(CH2)m; R1and R2independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.
REFERENCES:
patent: 3951982 (1976-04-01), Goel
patent: 5296485 (1994-03-01), Lubisch et al.
patent: 6107458 (2000-08-01), Ohki et al.
patent: WO 99/24406 (1999-05-01), None
patent: WO 02/076925 (2002-10-01), None
patent: WO 02/099388 (2002-12-01), None
patent: WO 2004/037257 (2004-05-01), None
patent: WO 2004/069792 (2004-08-01), None
Bakker R.A., Inflamm. Res. 53, 509-516, 2004.
Esbenshade et al., molecular intervention, 6, 77-88, 2006.
Kanatani Akio
Mizutani Sayaka
Ohtake Norikazu
Tokita Shigeru
Yoshimoto Ryo
Balasubramanian Venkataraman
Banyu Pharmaceutical Co. Ltd.
Krovatin William
Thies J. Eric
LandOfFree
Piperidine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4114159